Hospital Infection Therapeutics Market to Reach US$3.6 bn 2020, Hold Long Positions

Press Release   •   Jan 18, 2017 10:10 EST

Hospital-acquired infections are caused by bacterial, fungal, and viral pathogens. A majority of cases of hospital infections start from the intensive care units (ICUs). A large number of antimicrobial drugs have proven their competence in the treatment of a wide range of hospital infections.

Obtain the Upcoming Market Trends of Hospital Infection Therapeutics at:

This report predicts and analyzes the market for hospital infection therapeutics, on a regional and global level. The prediction is offered in terms of volume as well as revenue of the hospital infection therapeutics market in the forecasting horizon between 2014 and 2020. This research report includes the factors that fuel the market, as well as the restraining factors that will adversely influence the growth of the market during the forecast horizon.

In order to achieve a more crisp understanding of the hospital infection therapeutics market, TMR analysts have demonstrated an in-depth analysis of the value chain of the market. The business methodologies incorporated by the key players in the market are also elaborated in this report. The prominent players in the hospital infection therapeutics market, along with their competitive profiling as well as independent market shares across the four major geographical regions, have been included in this report. To get a know-how of the market dynamics, an evaluation of market attractiveness has also been incorporated in this study.

Overview of the Hospital Infection Therapeutics Market

The patients undergoing treatments in hospitals can develop infections in the course of their stay in the hospitals. These infections are called as hospital infections or hospital-acquired infections (HAI). These infections spread in healthcare environments such as outpatient surgery centers, rehabilitation centers, dialysis centers, hospitals, and nursing homes.

On the basis of the type of drug, the market for hospital infection therapeutics is segmented into antibacterial drugs, antifungal drugs, and antiviral drugs. The antibacterial drugs segment constituted the biggest share – 70.7% – in 2013 in the global market for hospital infection therapeutics. The antibacterial drugs segment is also anticipated to be the most swiftly developing segment in the market for global hospital infection in the forecast horizon from 2014 to 2020.

In terms of major types of infections, the market for hospital infection therapeutics is segmented into gastrointestinal disorders, bloodstream infections, hospital-acquired pneumonia (HAP), surgical site infections, urinary tract infections, and other hospital infections. The largest share in the global hospital infection therapeutics market was held by the hospital-acquired pneumonia segment in 2013, which represented more than 20% of the overall market. However, the segment of urinary tract infections is projected to expand at a rapid rate in the coming future.

On the basis of geography, the global hospital infection therapeutics market has been segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). On the basis of revenue, the market for hospital infection therapeutics was led by North America in 2013. After North America, the second biggest regional market was Europe. However, the hospital infection therapeutics market in Asia Pacific is predicted to witness the highest rate of growth throughout the forecast horizon.

The increase in the geriatric population, improved healthcare awareness, therapeutic drugs being highly in demand, and high occurrence of hospital infections are the key factors that stimulate the growth of the global hospital infection therapeutics market. Key factors that impede the growth of this market include rise in infection control, soaring number of multidrug-resistant bacterial strains, and hospital surveillance programs in emerging economies, which are leading to a reduced occurrence of hospital infections.

Read Current Market Analysis of Hospital Infection Therapeutics at:

Key players in the Hospital Infection Therapeutics Market

AstraZeneca plc, Actavis plc, Bayer AG, Cubist Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc., and Pfizer, Inc. are amongst the prominent players in the hospital infection therapeutics market.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453



Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.